Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BridgeBio Pharma Inc (BBIO) vs Best Buy Co Inc (BBY) Price & Performance

BridgeBio Pharma IncTrade
Best Buy Co IncTrade

Price performance (Past 24H)

Key statistics

BridgeBio Pharma Inc vs Best Buy Co Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Best Buy Co Inc trades at $84.31 (market cap $17.37B). The key difference: BridgeBio Pharma Inc and Best Buy Co Inc are close in size by market cap, and Best Buy Co Inc pays a 4.66% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.

BBIOBBY
Market Cap
$16.61B$17.37B
Sector
HealthConsumer Cyclical
52-Week High
$90.17$90.17
52-Week Low
$47.29$55.52
Enterprise Value
$18.16B$19.75B
Dividend Yield
4.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BridgeBio Pharma Inc

BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.

The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.

Best Buy Co Inc

Best Buy (BBY) trades at $82.00, up 2.47% today, with a bearish technical signal and mixed sentiment. Recent earnings beats and a forward P/E of 15.19 suggest reasonable valuation, but revenue has declined from $51.8B in 2022 to $41.5B in 2025. The company is testing smaller store formats and appointed a new CFO in August 2026, aiming to stabilize operations amid leadership changes.

Outlook is cautious; analyst consensus is a Hold with a $81.69 price target. Opportunities include cost control and dividend yield, but risks involve persistent revenue pressure, competitive threats, and execution risks from management turnover. Net cash flow turned positive in 2025, yet margin compression remains a concern for sustained growth.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BridgeBio Pharma Inc

BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.

Read more on BBIO

About Best Buy Co Inc

With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Read more on BBY